Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Sinsin Pharmaceutical Co., Ltd.
WARNING LETTER
•Sinsin Pharmaceutical Co., Ltd.•April 15, 2025

Sinsin Pharmaceutical Co., Ltd. – FDA Warning Letter, Apr 15, 2025

Record Details

Sinsin Pharmaceutical Co., Ltd. received a warning letter from the FDA on November 12, 2025, following a review conducted on April 15, 2025. The review focused on the company"s product labeling and online marketing for SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS, which are available for purchase in the United States. The FDA identified significant regulatory violations under the Federal Food, Drug, and Cosmetic Act (FD&C Act).

The main issues highlighted include the marketing of these products as unapproved new drugs and their misbranding. According to the FDA, these products are intended for use as external analgesics but do not conform to the conditions specified in the applicable OTC monograph (M017) for over-the-counter human use. Specifically, the active ingredients in these products, such as zinc oxide, mentha oil, chlorpheniramine maleate, and thymol, are not permitted under the monograph when used in combination or as sole ingredients. Consequently, the products are not generally recognized as safe and effective (GRASE) and are considered unapproved new drugs.

The FDA requires Sinsin Pharmaceutical to address these violations by ensuring compliance with federal law and FDA regulations. The company must investigate the causes of these violations, prevent their recurrence, and ensure all products meet legal requirements. Failure to adequately address these issues could result in further regulatory action. The letter serves as a formal notification and an opportunity for the company to rectify the identified concerns.

Company
Sinsin Pharmaceutical Co., Ltd.
Inspection date
April 15, 2025
Product type
Drugs
Office
Office of Unapproved Drugs & Labeling Compliance
Person
  • Tina Smith (Director)
View Company Profile

ID · f8734ffe-53c2-427e-a757-6ccb7ee68dc6

Violation Codes10
FD&C Act 505(a)FD&C Act 301(d)21.U.S.C. 355(a)21 U.S.C. 331(d)FD&C Act 502(ee)21 U.S.C. 352(ee)FD&C Act 301(a)21.U.S.C. 331(a)FD&C Act 201(g)(1)(B)21 U.S.C. 321(g)(1)(B)

Full citation text and observation details available on the Dashboard.

Other documents for Sinsin Pharmaceutical Co., Ltd.
  • 483 - 2025-02-14February 14, 2025
  • 483 - 2019-12-13December 13, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Sinsin Pharmaceutical Co., Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.